A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

HIV Infections Clinical Trial

Official title:

A Pilot Randomized Placebo-Controlled Trial Designed to Determine the Tolerability and Efficacy of Silymarin (Milk Thistle) vs. Placebo for the Treatment of Chronic Hepatitis C in HIV Infected Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00246363
• Other study ID #: GCO 02-1185
• Secondary ID: R21NR008860
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 27, 2005
• Last updated: September 14, 2011
• Start date: January 2005
• Est. completion date: December 2007

Study information

• Verified date: September 2011
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

There is some information available that indicates that Milk Thistle is an effective treatment for liver disease. This study will compare Milk Thistle with a placebo, (a medicine that looks just like Milk Thistle but does not contain any Milk Thistle) to see if people with both Hepatitis C and HIV infections show improvement or cure of Hepatitis C. The study will last one year.

Description:

Patients with many different diseases are requesting information from health care providers, (physicians and nurses) about alternative therapies. The paucity of evidence based information requires that rigidly structured clinical trials comparing dietary supplements, herbal products and other alternative modalities with either placebo or standard of care be conducted in a timely fashion. There is a body of evidence that Silymarin is both well tolerated and efficacious for the treatment of Hepatitis C. In patients co-infected with HIV & HCV, treatment choices are sometimes limited by intolerable toxicities of standard therapies for the treatment of HCV when combined with antiretroviral therapy for treatment of HIV. This study will seek to determine if Silymarin, an herbal product that is widely used, will be well tolerated and effective in slowing progression of liver damage in patients co-infected with HIV & HCV.

The Informed Consent Document contains all the required elements of informed consent as required by 21CFR50. The consent clearly states that this is research, participation is voluntary and that treatment with Silymarin may not be effective. Every effort has been made to outline whatever is known about any side effects. There are very few. All study participants are followed closely, are given their test results which are also shared with primary care providers. The investigators have convened a Data and Safety Monitoring Board and the Mount Sinai IRB has approved and will monitor the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women 18 years old and older

• Blood tests that are positive for a certain type of Hepatitis C known as

• HIV +

• Blood tests for liver function that indicate that the liver is working - must be obtained within one month of study entry

• CD4 counts and HIV viral loads obtained within one month of study entry

• (CD4 count <100 - eligible if HIV Viral Load <25,000)

• (CD4 >100 - eligible with any HIV Viral Load)

Exclusion Criteria:

• Women who are pregnant & breast-feeding & male partners of pregnant women

• Diagnosis of advanced liver disease

• Chronic liver disease other than Hepatitis C

• HIV related infection within two weeks of study entry

• Having had any organ transplant in the past including bone marrow

• History of mental illness including depression within three months of study entry and attempted suicide or hospitalization for the treatment of mental illness at any time in the past

• Chemotherapy treatment or treatment with steroids or other drugs that affect the immune system within six months of study entry

• Problems with alcohol of illegal drugs within one year of study entry. Patients on methadone will be allowed to enter the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• HIV Infections

Intervention

Drug:
• Silymarin
Silymarin (milk thistle)
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Mount Sinai School of Medicine	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Henry Sacks	National Institute of Nursing Research (NINR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression of liver damage	progression of liver damage	one year after enrollment	No

External Links

•   Link